Julia Playán-Escribano, Carlos Labrandero de Lera, Leticia Albert de la Torre, Alejandro Rodríguez-Ogando, Antonio Moreno-Galdó, Inmaculada Guillén Rodríguez, Anna Sabaté-Rotés, Amparo Moya-Bonora, Lina María Caicedo Cuenca, María Jesús del Cerro, on behalf of the REHIPED investigators
Hospital General Universitario Gregorio Marañón. Hospital Universitario del Sureste, Arganda del Rey. Universidad Complutense de Madrid. Hospital Universitario La Paz. Hospital Universitario 12 de Octubre. Hospital General Universitario Gregorio Marañón. Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona. Hospital Virgen del Rocío. Hospital Universitario La Fe. Clínica Shaio. Hospital Universitario Ramón y Cajal.
Spain and Columbia
Revista Española de Cardiología (English Edition)
Rev Esp Cardiol (Engl Ed) 2026;
DOI: 10.1016/j.rec.2026.03.006
Abstract
Introduction and objectives: Risk scores for pulmonary hypertension (PH) have been proven useful in adults. However, no risk score has been validated in pediatric populations. Our aim was to adapt the REVEAL Lite 2 score to pediatrics, including groups 1 (pulmonary arterial hypertension) and 3 (PH associated with lung diseases).
Methods: We used data from the REHIPED, which is the PH registry of the Spanish Society of Pediatric Cardiology and Congenital Heart Disease. The registry also incorporates some Colombian centers. Patients in group 1 and group 3 were included. The score was derived using machine learning. The contribution of each variable and its cutoffs were identified through gradient boosting. The REVEAL Lite 2 variables were normalized and entered into the model, along with each patient’s weight, sex, and age. Risk stratification into 3 categories (low, intermediate, and high risk) was performed.
Results: A total of 420 children were analyzed. The final model included functional class, age at diagnosis, heart rate, weight-for-height percentile, systolic blood pressure, natriuretic peptides, weight-for-age percentile, and 6-minute walk test. The area under the curve was 0.82, with an estimated area under the curve of 0.73 on unseen data. The log-rank P value for differences in transplant-free survival among the 3 risk strata (low, intermediate, and high) was < .001. HR for intermediate risk vs low risk was 3.10 (95%CI, 1.02-9.40; P = .046), and HR for high risk vs low risk was 12.30 (95%CI, 4.42-34.25; P < .001).
Conclusions: Our score adequately stratifies the risk of PH in the pediatric population, including infants, and is based on noninvasive variables.
Category
Diagnostic Testing for Pulmonary Vascular Disease. Non-invasive Testing
Diagnostic Testing for Pulmonary Vascular Disease. Risk Stratification
Mechanical and Computer Models of Pulmonary Vascular Disease and Therapy
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes